Depression and Survival in Patients With Head and Neck Cancer

Abstract

Background: The interplay between depression and cancer, particularly in patients with head and neck cancer, has garnered increasing attention in recent years. Literature Review: The subsequent investigation in 2018 revealed that while treating major depression in cancer patients alleviated depressive symptoms, it did not significantly improve survival rates (Mulick et al., 2018). This finding raises crucial questions regarding the efficacy of current treatment modalities, highlighting the complexity of cancer care where psychological and biological factors interplay. A critical review in 2019 further elaborated on the relationship between cancer-related inflammation and depression, noting the high prevalence of depressive symptoms across various cancer types, including head and neck cancers (C. McFarland et al., 2021). The authors emphasized the need for addressing mental health issues to improve overall patient outcomes, particularly as the burden of depression escalates with disease progression. Finally, a population-based cohort study conducted in 2020 reaffirmed the association between depression and poorer survival outcomes in head and neck cancer patients, particularly those with advanced disease stages (Huang et al., 2022). The study highlighted the necessity for integrated psychological care within oncology settings, as undetected depression often remains untreated, adversely affecting both mood and survival rates. Conclusion: In conclusion, the reviewed literature collectively underscores the intricate relationship between depression and survival in patients with head and neck cancer. There is a pressing need for comprehensive mental health assessments and interventions as part of standard cancer care. The findings suggest that addressing depressive symptoms could potentially enhance both the quality of life and survival rates among these patients, warranting further research to explore effective treatment strategies.